CLINICAL CANCER RESEARCH INCLUDES CANCER
VOL. 5, NO. 5, MAY 1999
Minireview
945 Development of Difluoromethylormthine (DFMO) as a Che-
moprevention Agent. Frank L. Meyskens, Jr. and Eugene W.
Gemer.
Advances in Brief
953 Phase I Study of (90)Y-labeled B72.3 Intraperitoneal Admin-
istration in Patients with Ovarian Cancer: Effect of Dose
and KDTA Coadministration on Pharmacokinetics and Tox-
icity. Michael G. Rosenblum, Claire F. Verschraegen, James L.
Murray, Andrzej P. Kudelka, Jacalyn Gano, Lawrence Cheung,
and John J. Kavanagh.
963 Centrosome Abnormalities in Pancreatic Ductal Carcinoma.
Norihiro Sato, Kazuhiro Mizurnoto, Masafumi Nakamura,
Kenjiro Nakamura, Masahiro Kusumoto, Hideaki Niiyama,
Takahiro Ogawa, and Masao Tanaka.
971 Molecular Detection of Telomerase-positive Circulating
Epithelial Cells in Metastatic Breast Cancer Patients.
Jean-Charles Soria, Laurent R. Gauthier, Eric Raymond,
Christine Granotier, Luc Morat, Jean-Pierre Armand, Francois
D. Boussin, and Laure Sabatier.
977 Overexpression of the Cyclin-dependent Kinase Inhibitor
pl6 Is Associated with Tumor Recurrence in Human Pros-
tate Cancer. Cheryl T. Lee, Paola Capodieci, Iman Osman,
Melissa Fazzari, Joseph Ferrara, Howard 1. Scher, and Carlos
Cordon-Cardo.
985 Receptor for Interleukin 13 Is a Marker and Therapeutic
Target for Human High-Grade Gliomas. Waldemar
Debinski, Denise M. Gibo, Stanley W. Hulet, James R. Connor,
and G. Yancey Gillespie.
991 Comparison of Features of Human Lung Cancer Cell Lines
and Their Corresponding Tumors. Ignacio I. Wistuba, David
Bryant, Carmen Behrens, Sara Milchgrub, Arvind K. Virmani,
Raheela Ashfaq, John D. Minna, and Adi F. Gazdar.
1001 Prognostic Significance of Elevated Cyclooxygenase 2 Ex-
pression in Primary, Resected Lung Adenocarcinomas.
Hiroyuki Achiwa, Yasushi Yatabe, Toyoaki Hida, Tetsuo
Kuroishi, Ken-ichi Kozaki, Shigeo Nakamura, Makoto Ogawa,
Takahiko Sugiura, Tetsuya Mitsudomi, and Takashi Takahashi.
1007 Cisplatin-induced Activation of Mitogen-activated Protein
Kinases in Ovarian Carcinoma Cells: Inhibition of Extra-
cellular Signal-regulated Kinase Activity Increases Sensitiv-
ity to Cisplatin. Diane L. Persons, Eugenia M. Yaziovitskaya
Wei Cui, and Jill C. Felling.
1015 Recombinant Adenovirus Expressing Wild-Type p53 Is An-
tiangiogenic: A Proposed Mechanism for Bystander Effect.
Masahiko Nishizaki, Toshiyoshi Fujiwara, Tohru Tanida, Akio
Hizuta, Hiroyuki Nishimori, Takashi Tokino, Yusuke
Nakamura Michael Bouvet, Jack A Roth and Noriaki Tanaka
Clinical Trials
1025 Locoregional Regulatory Peptide Receptor Targeting with
the Diffusible Somatostatin Analogue (90)Y-Labeled DOTA(o)-
D-Phe1-Tyr3octreotide (DOTATOC): A Pilot Study in Hu-
man Gliomas. Adrian Merlo, Oliver Hausmann, Morten
Wasner, Philipp Steiner, Andreas Otte, Eduard Jermann, Peter
Freitag, Jean-Claude Reubi, Jan Muller-Brand, Otmar Gratzl,
and Helmut R. Macke.
1035 Efficacy and Safety of Simultaneous linmunomagnetic
CU34+ Cell Selection and Breast Cancer Cell Purging in
Peripheral Blood Progenitor Cell Samples Used for Hema-
topoietic Rescue after High-Dose Therapy. Michael Mohr,
Eva Hilgenfeld, Thomas Fietz, Berthold Hoppe, Michael
Koenigsmann, Marianne Hoffmann, Wolfgang LJ. Knauf, Uwe
Cassens, Walter Sibrowski, Joachim Kienast, Eckhard Thiel,
and Wolfgang E. Berdel.
Molecular Oncology, Markers,
Clinical Correlates
1041 Vascular Stroma Formation in Carcinoma in Situ, Invasive
Carcinoma, and Metastatic Carcinoma of the Breast.
Lawrence F. Brown, Anthony J. Guidi, Stuart J. Schnitt,
Livingston Van De Water, Maria Luisa lruela-Arispe, Tet-Kin
Yeo, Kathi Tognazzi, and Harold F. Dvorak.
1057 Paradoxical Correlations of Cyclin-dependent Kinase Inhib-
itors p21wafl/cipl and p27kipl in Metastatic Colorectal
Carcinoma. Jonathan D. Cheng, Bruce A. Werness, James S.
Babb, and Neal J. Meropol.
1063 Alterations in Expression of Basic Fibroblast Growth Factor
(FGF) 2 and Its Receptor FGFR-I in Human Prostate Can-
cer. Dipak Giri, Frederic Ropiquet, and Michael lttmann.
1073 Expression of the Hyaluronan Receptor, CD44S, in Epithe-
lial Ovarian Cancer Is an Independent Predictor of Sur-
vival. Sanjiv Kayastha, Andrew N. Freedman, M. Steven Piver,
Jhansi Mukkamalla, Maritza Romero-Guittierez, and Bruce A.
Werness.
1077 Estrogen Receptor Methylation Is Associated with Im-
proved Survival in Adult Acute Myeloid Leukemia. Qing Li,
Kenneth J. Kopecky, Avinash Mohan, Cheryl L. Willman,
Frederick R. Appelbaum, James K. Weick, and Jean-Pierre J.
Issa.
1085 Disrupted p53 Function as Predictor of Treatment Failure
and Poor Prognosis in B- and T-Cell Non-Hodgkin's Lym-
phoma. Michael B. Miller, Anne-Marie Gerdes, Karsten
Skj0dt, Leif S. Mortensen, and Niels T. Pedersen.
1093 Endothclial Cell Nitric Oxide Synthase in Peritumoral Mi-
crovessels Is a Favorable Prognostic Indicator in Premeno-
pausal Breast Cancer Patients. Kirsten Mortensen, Susanne
Hoick, lb Jarle Christensen, Jan Skouv, David M. Hougaard,
Jens Blom, and Lars-inge Larsson.
1099 Detection of Melanoma Ctils in the Blood of Melanoma
Patients hv Melanoma-inhibitorv Activity (MIA) Reverse
Transcription-PCR. Marcus Muhlbauer. Nicole Langenhach.
Wilhelm Stol?., Rliediger Hein, M. Lancitlialer, Reinhard
Buettner, and Anja-Katrin Bosserhoff.
1107 Macropliage Inriltration and Heine Oxygenase-I Expression
Correlate with Angiogencsis in Human Glioinas. Akihil'o
Nishie, Mayumi Ono, Tadallisa Shono, Junichi Fliklishi,
Michihil-o Otsubo, Hitoshi Oiiolie, Yushi Ito, Takanori liiaimira.
Kiyonubli Ikezaki, Masashi Fliklii, TOILI lwaki, and Michihiko
Kuwano.
1115 Matrix IVIetalloproteinase Production by Bone Marrow
Mononuclear Cells from Normal Individuals and Patients
with Acute and Chronic Myeloid Lenkemia or Myelodys-
plastic Syndromes. Christian Ries, Florian Lolier, Chlianbing
Zang, ManFred G. Isinair, and Petro E. Petrides.
1125 Increased Serum Angiogenin Concentration in Colorectal
Cancer Is Correlated with Cancer Progression. Shouji
Shirnoyama, Ka/uki Yamasaki, Masaki Kawahara, and Micilio
Kaininishi.
1131 Significance of Thymidinc Phosphorylase as a Marker of
Protumor Monocytes in Breast Cancer. Masakazu Toi,
Takayliki Ueno, Hiroslii Matsuinolo, Hisaslii Saji, Nobliaki
Funata, Morio Koike, and Takeshi Toininaga.
1139 Prognostic Significance of Allelic Imbalances on Chromo-
some 9p in Stage I Non-Small Cell Lung Carcinoma. Yoshio
Tomizawa, Jun-ichi Adacbi, Takashi Kohno, Klinihiro Hamada,
Ryusei Saito, Masayuki Noguchi, Yoshihiro Matsuno, Setsuo
Hirobashi, Naohito Yamaguchi, and Jun Yokola.
1147 Detection of Mutations of p53 Tumor Suppressor Cicne in
Pancreatic Juice and Its Application to Diagnosis of Patients
with Pancreatic Cancer: Comparison with K-ras Mutation.
Yaslishi Yamagncbi, Hiroyliki Watanabe, Songur Yrdiran,
Koushiroli Obtslibo, Yoshibaru Motoo, Takasi Okai, and Norio
Sawabu.
1155 Telomere Stability Is Frequently Impaired in High-Risk
Groups of Patients with Myelodysplastic Syndromes. Junko
H. Obyasbiki, Hiroshi lwama, NaoyLiki Yahata, Keiko Ando,
Shigeflimi Hayashi, Jerry W. Sbay, and Kazurna Ohyashiki.
Experimental Therapeutics, Preclinical
Pharmacology
1161 Predictive Value of Preclinical Toxicology Studies for Plat-
inum Anticancer Drugs. Diana L. Clark, Paul A. Andrews,
David D. Smith, Joseph J. DeGeorge, Robert L. Justice, and
Julie G. Beilz.
1169 An Improved Nonisotopic Test to Screen a Large Series of
New Inhibitor Molecules of Poly(ADP-ribose) Polymerase
Activity for Therapeutic Applications. Patrice Decker,
Everson Alves Miranda, Gilbert de Murcia, and Sylviane
Mliller.
1173 Primary T-Cell and Activated Macrophage Response Asso-
ciated with Tumor Protection Using Peptide/Poly-YV-Acetyl
Glucosamine Vaccination. Nathalie Maitre, Jason M. Brown,
Marina Derncheva, Joseph R. Kelley, Mark A. Lockett, John
Volirnakis, and David J. Cole.
1183 Treatment of Neoplastic Meningitis With intrathecal Iemo-
zolomide. John H. Sampson. Gary E. .archer. Alan T.
Villavicencio, Roger E. McLendon, Allan H.' Friedman, W.
Robert Bishop, Darell D. Bigner, and Henry S. Friedman.
1189 Cellular Pharmacology of the Combination of the DNA
Topoisomerase I Inhibitor SN-38 and the Diaminocyclohex-
ane Platinum Derivative Oxaliplatin. Nadia Zeghari-Squalli,
Eric Raymond, Esteban Cvitkovic, and Francois Goldwasser.
Cancer Biology, Immunology, Cytokines
1197 Activation of Nuclear Factor-KB in Human Metastatic Mel-
anoma Cells and the Effect of Oxidative Stress. Frank L.
Meyskens, Jr„ Jlilie A. Buckineier, Susan E. McNulty, and
Niloutar B. Tohidian.
1203 Autologous High-Killing Cytotoxic T Lymphocytes against
Human Lung Cancer Are Induced Using Intericukin (IL)-
lp, IL-2, IL-4, and IL-6: Possible Involvement ofDendritic
Cells. Yasuo Saijo, Xin Hong, Masashi Tanaka, Ryushi
Tazawa, Shu Qin Liu, Kaoru Saijo, Tadao Ohno, Kaoru Koike,
Kazuhiro Ohkuda, Ken Satoh, and Toshihiro Nukiwa.
1211 Suppression of Telomerase, Reexpression of KAII, and Ab-
rogation of Tumorigenicity by Nerve Growth Factor in
Prostate Cancer Cell Lines. Sandra Sigala, Isabella Faraoni,
Daniela Botticini, Marcelo Paez-Pereda, Cristina Missale, Enzo
Boninassar, and PierFranco Spano.
1219 Mechanisms of Apoptosis in T Cells from Patients with
Renal Cell Carcinoma. Robert G. Uzzo, Patricia Rayman,
Vladimir Kolenko, Peter E. Clark, Tracy Bloom, A. Michelle
Ward, Luis Molto, Charles Tannenbaurn, Lydia J. Worford,
Ronald Bukowski, Raymond Tubbs, Eric D. Hsi, Neil H.
Bander, Andrew C. Novick, and James H. Finke.
1231 Loss of Heterozygosity of the Rb Gene 'Correlates with pRb
Protein Expression and Associates with p53 Alteration in
Human Esophageal Cancer. Eric Poe Xing, Guang-Yu Yang,
Li-Dong Wang, Stephanie Tao Shi, and Chung S. Yang.
1241 AACR Bulletin Board
Annual Meeting
Call for Nominations for 2000 AACR-Pezcoller International Award
for Cancer Research
Call for Nominations for AACR Awards
AACR Special Conferences in Cancer Research
1242 Author Index
i Instructions for Authors
BACK OF ISSUE:
Call for Abstracts for
AACR-NCI-EORTC International
Conference on Molecular Targets
and Cancer Therapeutics
Abstract Deadline: July 15, 1999
_______________________________________
Clinical Cancer Research
Volume 5, Number 6, June 1999
CONTENT
Expression of Transforming Growth Factor beta Type II Re- 1243
ceptors in Head and Neck Squamous Cell Carcinoma. Carlos
A. Muro-Cacho, Meredith Anderson, Joehassin Cordero, and
Teresita Munoz-Antonia.
Reduction of BRCAI Protein Expression in Japanese Spo- 1249
radic Breast Carcinomas and Its Frequent Loss in BRCAI-
associated Cases. Kiyotsugu Yoshikawa, Kazuo Honda,
Takashi Inamoto, Hisashi Shinohara, Akira Yamauchi, Kenji
Suga, Takazo Okuyama, Toshihide Shirnada, Hiroshi Kodama,
Shinzaburo Noguchi, Adi F. Gazdar, Yoshio Yamaoka, and Rei
Takahashi.
Spontaneous ex Vivo Apoptosis of Peripheral Blood Mono- 1263
nuclear Cells in Patients with Head and Neck Cancer. Takao
Saito, Iris KUSS, Grzegorz Dworacki, William Gooding, Jonas
T. Johnson, and Theresa L. Whiteside.
Detection of Subclinical Cancers by Prostate-specific Anti- 1275
gen Screening in Asymptomatic Men from High-Risk Pros-
tate Cancer Families. Mika P. Matikainen, Johanna
Schleutker, Pertti Morsky, Olli-P. Kallioniemi, and Teuvo L. J.
Tammela.
Generation of Anti-p53 Cytotoxic T Lymphocytes from Hu- 1281
man Peripheral Blood Using Autologous Dendritic Cells.
Kazuaki Chikamatsu, Koji Nakano, Walter J. Storkus, Ettore
Appella, Michael T. Lotze, Theresa L. Whiteside, and Albert B.
DeLeo.
Clinical Trials
Generation of Immunity to the HER-2/neu Oncogenic Pro- 1289
tein in Patients with Breast and Ovarian Cancer Using a
Peptide-based Vaccine. Mary L. Disis, Kenneth H. Grabstein,
Paul R. Sleath, and Martin A. Cheever.
A Phase I Study of Continuous Infusion Doxorubicin and 1299
Paclitaxel Chemotherapy with Granulocyte Colony-Stimu-0-
lating Factor for Relapsed Epithelial Ovarian Cancer. Linda
R. Duska, Richard Penson, Jeffrey G. Supko, Dianne M.
Finkelstein, Thomas Makastorsis, Joan Gallagher, Karen
Borden, Annekathryn Goodman, Arlan F. Füller, Najmosama
Nikrui, and Michael V. Seiden.
Rhenium-186-labeled Hydroxyethylidene Diphosphonate 1307
Dosimetry and Dosing Guidelines for the Palliation of Skel-
etal Metastases from Androgen-independent Prostate Can-
cer. Martin C. Graham, Howard l. Scher, Gen-Bao Liu, Samuel
D-J. Yeh, Tracy Curley, Farhad Daghighian, Stanley J.
Goldsmith, and Steven M. Larson.
Long Survival of Patients with Small Cell Lung Cancer after 1319
Adjuvant Treatment with the Anti-ldiotypic Antibody
BEC2 Plus Bacillus Calmette-Guerin. Stefan C. Grant, Mark
G. Kris, Alan N. Houghton, and Paul B. Chapman.
Pharmacokinetics and Pharmacodynamics of 9-Ami- 1325
nocamptothecin Infused Over 72 Hours in Phase II Studies.
Hironoba Minami, Thomas E. Lad, M. Kelly Nicholas, Everett
E. Vokes, and Mark J. Ratain.
A Phase I Study of Active Immunotherapy with Carcino- 1331
embryonic Antigen Peptide (CAP-D-pulsed, Autologous
Human Cultured Dendritic Cells in Patients with Metastatic
Malignancies Expressing Carcinoembryonic Antigen.
Michael A. Morse, Yuping Deng, Doris Coleman, Shelley Hull,
Eva Kitrell-Fisher, Smita Nair, Jeffrey Schlom, Mary-Ellen
Ryback, and H. Kirn Lyerly.
A Phase I Trial of Calcitriol ( 1,25-Dihydroxycholccalciferol) 1339
in Patients with Advanced Malignancy. David C. Smith,
Candace S. Johnson, Catherine C. Freeman, Josephia Muindi,
John W. Wilson, and Donald L. Trump.
High Inter- and Intrapatient Variation in 5-Fluorouracil 1374
Plasma Concentrations during a Prolonged Drug Infusion.
Chris H. Takimoto, Lorrin K. Yee, David J. Venzon, Barbara
Schüler, Frank Grollman, Chetin Chabuk, J. Michael Hamilton,
Alice P. Chen, Carmen J. Allegra, and Jean L. Grem.
Immunogenicity of Granulocyte-Macrophage Colony-stim- 1353
ulating Factor (GM-CSF) Products in Patients undergoing
Combination Therapy with GM-CSF. Meenu Wadhwa,
Anna-Lena Hjelm Skog, Chris Bird, Peter Ragnhammar, Maria
Lilljefors, Rose Gaines-Das, Hakan Mellstedt, and Robin Thorpe.
Phase I Study of Transforming Growth Factor-p3 Mouth- 1363
washes for Prevention of Chemotherapy-induced Mucositis.
A. N. Machteid Wymenga, Winette T. A. van der Graaf, Lieuwe
S. Hofstra, Fred K. L. Spijkervet, Wim Timens, Hetty
Timmer-Bosscha, Wim J. Sluiter, A. H. J. A. W. van Buuren,
Nanno H. Mulder, and Elisabeth G. E. de Vries.
Molecular Oncology, Markers,
Clinical Correlates
Expression of Proinflammatory and Proangiogenic Cyto- 1369
kines in Patients with Head and Neck Cancer. Zhong Chen,
Pramit S. Malhotra, Giovana R. Thomas, Frank G. Ondrey,
Dianne C. Duffey, Conrad W. Smith, lleana Enamorado, Ning
T. Yeh, Glenn S. Kroog, Susan Rudy, Linda McCullagh, Shaker
Mousa, Matha Quezado, Laune L. Herscher, and Carter Van
Waes.
Detection of erb B-2 Amplifications in Tumors and Sera 1381
from Esophageal Carcinoma Patients. Pei-Wen Chiang,
David G. Beer, Wan-Li Wei, Mark B. Orringer, and David M.
Kurnit.
Absence of PTEN Germ-Line Mutations in Men with a 1387
Potential Inherited Predisposition to Prostate Cancer.
Kathleen A. Cooney, Hui C. Tsou, Elizabeth M. Petty, Susan
Miesfeldt, Xiao Li Ping, Alexandra C. Gruener, and Monica
Peacocke.
Antinuclear Antibodies as Potential Markers of Lung Can- 1393
cer. Felix Fernandez-Madrid, Pamela J. VandeVord, Xin Yang,
Robert L. Karvonen, Pippa M. Simpson, Michael J. Kraut, Jose
L. Granda, and John E. Tomkiel.
Rearrangements of Chromosome Band 1p36 in Non- 1401
Hodgkins Lymphoma. Bhavana J. Dave, Michelle M. Hess,
Diane L. Pickering, Dianna H. Zaieski, Andrea L. Pfeifer,
Dennis D. Weisenburger, James 0. Armitage, and Warren G.
Sänger.
Enhanced Expression of Indudble Nitric Oxide Synthase 1411
and Nitrotyrosinc in Gastric Mucosa of Gastric Cancer
Patients. Toyoko Goto, Ken Haruma, Yasuhiko Kitadai,
Masanori lto, Masaharu Yoshihara, Koji Surnii, Norihiko
Hayakawa, and Goro Kajiyama.
Loss of Heterozygosity Accumulation in Primary Breast 1417
Carcinomas and Additionally in Corresponding Distant Mc-
tastascs Is Associated with Poor Outcome. Monika Hampi,
Jürgen A. Hampi, GilFe Reiss, Gabriele Schackert, Hans-D.
Saeger, and Hans K. Schackert.
Prognostic Value of Circulating Soluble E-Selectin Concen- 1427
trations in Node-negative Breast Cancer Patients. Mohanied
Hebbar, Francoise Revillion, Marie-Michele Louchez, Charles
Foumier, Jacques Bonneterre, and Jean-Philippe Peyrat.
Chromosomal Abnormalities in Glioblastoma Multiforme 1435
by Comparative Genomic Hybridization: Correlation with
Radiation Treatment Outcome. Stephen L. Huhn, Gayatry
Mohapatra, Andrew Bollen, Kathleen Lamborn, Michael D.
Prados, and Burt G. Feuerstein.
Infrequent Germ-line Mutation of the E-cadherin Gene in 1445
Japanese Familial Gastric Cancer Kindreds. Satoru lida,
Yoshimitsu Akiyarna, Wataru Ichikawa, Toshiki Yamashita,
Tadashi Nomizu, Zenro Nihei, Kenichi Sugihara, and Yasuhito
Yuasa.
The Prognostic Significance of Tumor-associated Antigen 1449
22-1-1 Expression in Adenocarcinoma of the uterine Cervix.
Tsunehisa Kaku, Kenzo Sonoda, Toshiharu Kamura, Toshio
Hirakawa, Kunihiro Sakai, Satoshi Amada, Shinji Ogawa,
Hiroaki Kobayashi, Manabu Nakashima, Takeshi Watanabe,
and Hitoo Nakano.
Differential Expression of the Retinoblastoma Gene Family 1455
Members in Choroidal Melanoma: Prognostic Significance.
Mina Massaro-Giordano, Gianluca Baldi, Antonio De Luca,
Alfonso Baldi, and Antonio Giordano.
Biological Characterization of Subgroups of Squamous Cell 1459
Lung Carcinomas. Jürgen Mattem, Reet Koomagi, and
Manfred Voirn.
Expression of the 67-kDa Laminin Receptor in Acute Mye- 1465
loid Leukemia Cells Mediates Adhesion to Laminin and Is
Frequently Associated with Monocytic Differentiation.
Nunzia Montuori, Carmine Selleri, Antonio Maria Risitano,
Anna Maria Raiola, Pia Ragno, Luigi Del Vecchio, Bruno
Rotoli, and Guido Rossi.
Increased Scrum and Urinary Levels of a Parathyroid 1473
Hormone-related Protein COOH Terminus in Non-Small
Cell Lung Cancer Patients. Yutaka Nishigaki, Yoshinobu
Ohsaki, Eri Toyoshima, and Kenjiro Kikuchi.
Human Telomerase Reverse Transcriptase (hTERT) Gene 1483
Expression in Thyroid Neoplasms. Motoyasu Saji, Steve
Xydas, William H. Westra, Chien-Ko Liang, Douglas P. dark,
Robert Udelsman, Christopher B. Umbricht, Saraswati
Sukumar, and Martha A. Zeiger.
High-Level Expression of EPHB6, EFNB2, and EFNB3 Is 1491
Associated with Low Tumor Stage and High TrkA Expres-
sion in Human Neuroblastomas. Xao X. Tang, Audrey E.
Evans, Huaqing Zhao, Avital Cnaan, Wendy London, Susan L.
Cohn, Garrett M. Brodeur, and Naohiko Ikegaki.
Messenger RNA Determination of Estrogen Receptor, Pro- 1497
gestcrone Receptor, pS2, and Plasminogen Activator Inhib-
itor-1 by Competitive Reverse Transcription-Polymerase
Chain Reaction in Human Breast Cancer. Dan Tong,
Christian Schneeberger, Klaus Czerwenka, Rita K. Schinutzier,
Paul Speiser, Elisabeth Kucera, Nicole Concin, Ernst Kubista,
Sepp Leodolter, and Robert Zeillinger.
Decreased Expression of Retinoic Acid Receptors, Trans- 1503
forming Growth Factor P, Involucrin, and Cornifin in Cer-
vical Intraepithelial Neoplasia. Xiao-Chun Xu, Michele F.
Mitchell, Elvio Silva, Anton Jetten, and Reuben Lotan.
Phenylbutyratc Induces Cell Differentiation and Modulates 1509
Epstein-Barr Virus Gene Expression in Burkitt's Lym-
phoma Cells. Matia Bar-Ner, Alain Thibault, Maria Tsokos, lan
T. Magrath, and Dvorit Samid.
Ionizing Radiation Improves Survival in Mice Bearing In- 1517
tracranial High-Grade Gliomas Injected with Genetically
Modified Herpes Simplex Virus. Jeffrey D. Bradley, Yasushi
Kataoka, Sunil Advani, Su Mi Chung, Ramin B. Arani, G.
Yancey Gillespie, Richard J. Whitley, James M. Markert,
Bernard Roizman, and Ralph R. Weichselbaum.
Use of Carrier Cells to Deliver a Replication-selective Her- 1523
pes Simplex Virus-1 Mutant for the Intraperitoneal Ther-
apy of Epithelial Ovarian Cancer. George Coukos, Antonis
Makrigiannakis, Eugene H. Kang, David Caparelli, Ivor
Benjamin, Larry R. Kaiser, Stephen C. Rubin, Steven M.
Albeida, and Katherine L. Molnar-Kimber.
(125) 1-labeled Anti-Epidermal Growth Factor Rcccptor-vlll 1539
Single-Chain Fv Exhibits Specific and High-Level Targeting
of Glioma Xenografts. Chien-Tsun Kuan, Craig J. Reist,
Catherine F. Foulon, lan A. J. Lorimer, Gary Archer, Charles N.
Pegram, Ira Pastan, Michael R. Zalutsky, and Darell D. Bigner.
Combination Surgery and Nonviral Intcrieukin 2 Gene 1551
Therapy for Head and Neck Cancer. Daqing Li, Wen Jiang,
Jeffery S. Bishop, Robert Ralston, and Bert W. O'Malley, Jr.
Purging of Contaminating Breast Cancer Cells from Hema- 1557
topoietic Stem Cell Grafts by Adenoviral GAL-TEK Gene
Therapy and Magnetic Antibody Cell Separation. Frank C.
Marini, Virginia Snell, Qingnan Yu, Xin Zhang, S. Eva
Singletary, Richard Champlin, and Michael Andreeff.
Structure-based Design of Specific Inhibitors of Janus Ki- 1569
nase 3 as Apoptosis-inducing Antilcukemic Agents. Elise A.
Sudbeck, Xing-Ping Liu, Rama Krishna Naria, Sandeep
Mahajan, Sutapa Ghosh, Chen Mao, and Fatih M. Uckun.
Penetration of Anticancer Drugs through Solid Tissue: A 1583
Factor That Limits the Effectiveness of Chemotherapy for
Solid Tumors. Jonathan K. Tunggal, David S. M. Cowan,
Hafsa Shaikh, and lan F. Tannock.
Vitronectin, a Glioma-derived Extracellular Matrix Protein, 1587
Protects Tumor Cells from Apoptotic Death. Joon H. Uhm,
Nora P. Dooley, Athanassios P. Kyritsis, Jasti S. Rao, and
Candece L. Gladson.
Cancer Biology. Immunology, Cytokines
CLARI, a Novel Gene That Exhibits Enhanced Expression 1595
in Advanced Human Prostate Cancer. Rachel H. Rondinelli
and James V. Tricoli.
AACR Bulletin Board 1603
Annual Meeting
Call for Nominations for 2000 AACR-Pezcoller International Award
for Cancer Research
Call for Nominations for AACR Awards
AACR Special Conferences in Cancer Research
Author Index 1604
i Instructions for Authors
_______________________________________
CLINICAL CANCER RESEARCH INCLUDES CANCER
VOL. 5, NO. 11, SUPLEMMENT, NOVEMBER 1999
Program Committee and Special Committee for Review of Abstracts .......................................................... vi
Regular Abstracts: Poster Sessions
Poster Session 1 ..................................................................................................................................... 3729s
Section 1: Phase I Clinical Trials: New Agents, Antiangiogenesis, and Molecular Endpoints................ 3729s
Section 2: Growth Factors and Their Responses (Including Antihormonal) .......................................... 3734s
Section 3: Metastasis and Invasion Targets .............................................................................................. 3739s
Section 4: Fas Pathways/Growth Factors: Biology and Therapeutics ...................................................... 3744s
Section 5: Kinase Inhibitors .................................................................................................................... 3749s
Poster Session 2 ...................................................................................................................................... 3754s
Section 1: Cell Cycle Targets: p53, Cyclins, Cyclin-dependent Kinases.................................................. 3754s
Section 2: Cellular Therapy, Vaccines, and Immunologic Targets .......................................................... 3758s
Section 3: New Intracellular Targets ........................................................................................................ 3763s
Section 4: Tumor Physiology: Hypoxia, Radiosensitization, and New Extracellular Targets.................. 3768s
Section 5: Phase II Studies with Molecular Endpoints ............................................................................ 3772s
Poster Session 3 ...................................................................................................................................... 3776s
Section 1: Genomics and High Throughput Screens For Target Discovery
(Arrays and Chips)/Signal Transduction (Related to Gene Expression) .................................................. 3776s
Section 2: Structure-based Drug Design/Agents with Unknown or Uncertain Targets .......................... 3780s
Section 3: New Agents.............................................................................................................................. 3784s
Section 4: Marine Compounds and Other Natural Products, Synthetic Approaches ............................ 3789s
Section 5: Phase I Clinical trials: Derivatives, New Formulations, and Combinations.......................... 3794s
Poster Session 4 ...................................................................................................................................... 3800s
Section 1: Signal Transduction/Signaling Targets .................................................................................... 3800s
Section 2: Cytokines ................................................................................................................................ 3804s
Section 3: Antiangiogenesis/Antivascular Targets .................................................................................... 3808s
Section 4: Cell Biology-based Strategies: Apoptosis and Differentiation ................................................ 3813s
Section 5: Drug Delivery, Prodrugs, and Toxicology................................................................................ 3818s
Poster Session 5 ...................................................................................................................................... 3824s
Section 1: Molecular Markers and Tumor Imaging: Diagnosis, Progression, and Drug Responses ........ 3824s
Section 2: Telomerase and Gene Therapy-based Technology.................................................................. 3828s
Section 3: Drug Resistance/Modifiers ...................................................................................................... 3832s
Section 4: Preclinical Pharmacokinetics/Pharmacodynamics.................................................................. 3837s
Section 5: Drug Design, Metabolism, and Pharmacogenetics ................................................................ 3841s
Poster Session 6 ...................................................................................................................................... 3846s
Section 1: DNA-targeted Strategies: Oligodeoxynucleotides and Modulation of Repair Pathways........ 3846s
Section 2: DNA-interactive Agents .......................................................................................................... 3851s
Section 3: Tubulin-interactive Agents ...................................................................................................... 3855s
Section 4: Antifolates and Topoisomerase Inhibitors .............................................................................. 3860s
Section 5: Chemoprevention: Targets, Models, Biomarkers, and Trials .................................................. 3864s
Invited Abstracts: Plenary Sessions ...................................................................................................... 3869s
Plenary Session 3: Chemistry: Generation of Diversity .......................................................................... 3869s
Plenary Session 4: Biology and Target Selection II .................................................................................. 3869s
Plenary Session 5: Preclinical Development ............................................................................................ 3869s
Plenary Session 6: Imaging Molecular Targets ........................................................................................ 3870s
Plenary Session 7: New Opportunities for DNA and Microtubules ........................................................ 3872s
Plenary Session 9: Changing a Concept into a Drug: The Art of Patience ............................................ 3873s
Invited Abstracts: Workshops ................................................................................................................ 3875s
Workshop 1: Relevance of In Vivo Models for Target-directed Anticancer Drug Development ............ 3875s
Workshop 3: Cytostatic Agents: Methodology of Phase 1/11 Trials.......................................................... 3876s
Workshop 6: New Cytokines and Cell-based Therapy of Cancer............................................................ 3876s
Workshop 7: Prevention Targets .............................................................................................................. 3877s
Workshop 8: The Tumor Microenvironment ......................................................................................... .3877s
Workshop 12: Signal Transduction Targets in Cancer Drug Discovery .................................................. 3879s
Author Index .......................................................................................................................................... 3880s
Subject Index .......................................................................................................................................... 3893s